SV BR1 GM breast cancer vaccine companion diagnostic - Briacell Therapeutics

Drug Profile

SV BR1 GM breast cancer vaccine companion diagnostic - Briacell Therapeutics

Alternative Names: BriaDx™; BriaVax™ companion diagnostic - briacell; BriaVax™ DX -Briacell

Latest Information Update: 02 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BriaCell Therapeutics Corp
  • Class Cancer vaccines; Gene therapies; Immunotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 29 Nov 2016 BriaCell Therapeutics files for patent protection with the US Patent and Trademark Office for SV BR1 GM breast cancer vaccine companion diagnostic in USA
  • 14 Sep 2015 Preclinical trials in Breast cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top